National Taiwan University to Serve as Trial Site for Troubled San Diego Interferon Developer

The National Taiwan University Hospital will serve as a trial site for an investigational therapy for oral warts in HIV positive patients. The product, VELDONA&reg;, has been granted Orphan Drug Designation in the United States by the U.S. Food and Drug Administration. This clinical study announcement is based on an aims to provide new treatment options for individuals living with HIV, a virus that affected approximately 39.9 million people globally in 2023.
Developed by San Diego-based Ainos Inc. (NASDAQ: AIMD), described as a healthcare company specializing in AI-driven diagnostics and low-dose interferon therapies, the company goes back to 1984 when it was associated with its founding on core technology of non-injectable interferon alpha. They are a penny stock biotech trading at $0.48 per share.